| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/19/2002 | CA2441174A1 Novel anti-adhesive compounds and uses thereof |
| 09/19/2002 | CA2441088A1 1-butyric acid derivatives such as carbomethoxypropionyl cyanide or leflunomide derivatives, and the therapeutic use thereof |
| 09/19/2002 | CA2440973A1 Use of steroid derivatives for the treatment of a benighn and/or malignant tumour |
| 09/19/2002 | CA2440834A1 Anti-epileptogenic agents |
| 09/19/2002 | CA2440757A1 Substituted tetracycline compounds as synergistic antifungal agents |
| 09/19/2002 | CA2440647A1 P-thienylbenzyl-amides serving as agonists of angiotensin-(1-7)-receptors, method for the production thereof, their use and pharmaceutical preparations containing the same |
| 09/19/2002 | CA2440618A1 Immunoglobulin superfamily proteins |
| 09/19/2002 | CA2440555A1 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| 09/19/2002 | CA2440552A1 Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy |
| 09/19/2002 | CA2440374A1 A pharmaceutical composition for the treatment of depression comprising the ep1 antagonist as active ingredient |
| 09/19/2002 | CA2440284A1 Ph-dependent nmda receptor antagonists |
| 09/19/2002 | CA2440225A1 Taxane prodrugs |
| 09/19/2002 | CA2440211A1 Benzimidazole anti-inflammatory compounds |
| 09/19/2002 | CA2440208A1 Tumour targeting prodrugs activated by metallo matrixproteinases |
| 09/19/2002 | CA2440144A1 Methods for reducing fat by administration of adiponectin |
| 09/19/2002 | CA2439920A1 Antihypertensive agent and cholesterol absorption inhibitor combination therapy |
| 09/19/2002 | CA2439897A1 Enzyme-activated cytostatic conjugates with integrin ligands |
| 09/19/2002 | CA2439853A1 Use of thiolutin dioxide and its derivatives in the manufacture of a medicament for the treatment of cns disorders and a process for the preparation thereof |
| 09/19/2002 | CA2439735A1 Igf antagonist peptides |
| 09/19/2002 | CA2439653A1 Remedies for arthritis deformans and remedies for rheumatoid arthritis |
| 09/19/2002 | CA2439637A1 Human serpin polypeptides |
| 09/19/2002 | CA2439612A1 Modulation of smooth muscle cell proliferation |
| 09/19/2002 | CA2438874A1 Fluorinated trienes and their use as rxr modulators |
| 09/19/2002 | CA2438586A1 Retinoid x receptor modulators |
| 09/19/2002 | CA2438164A1 Use of preparations containing selenite or selenate |
| 09/19/2002 | CA2437958A1 Polymeric immunoglobulin fusion proteins that target low-affinity fc.gamma.receptors |
| 09/19/2002 | CA2436083A1 Use of dual h3/m2 antagonists in the treatment of cognition deficit disorders |
| 09/19/2002 | CA2433353A1 Crystals of whole antibodies and fragments thereof and methods for making and using them |
| 09/18/2002 | WO2001070678A2 Substituted biphenyl derivatives |
| 09/18/2002 | EP1241254A1 Apoptosis inhibitory polypeptide, gene and polynucleotide encoding it and compositions containing the same |
| 09/18/2002 | EP1241178A1 Process for producing functional silk fibroin and utilization of the same |
| 09/18/2002 | EP1241176A1 Purine derivatives for the treatment of ischemia |
| 09/18/2002 | EP1241170A2 Pyrazolopyrimidine derivatives |
| 09/18/2002 | EP1241169A1 Isoindoloindolone derivatives, process for their preparation and pharmaceutical compositions containing them |
| 09/18/2002 | EP1241168A1 Human NK3 receptor-selective antagonist compounds, process for their obtention and pharmaceutical compositons containing them |
| 09/18/2002 | EP1240906A1 Preventives or remedies for arrhythmia |
| 09/18/2002 | EP1240902A1 Carbonyl stress-ameliorating agents |
| 09/18/2002 | EP1240899A2 Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections |
| 09/18/2002 | EP1240525A2 Sodium channels as targets for amyloid beta |
| 09/18/2002 | EP1240358A1 T1 receptor-like ligand ii and uses thereof |
| 09/18/2002 | EP1240352A2 Molecules derived from mechanism based drug design |
| 09/18/2002 | EP1240343A2 Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression |
| 09/18/2002 | EP1240337A2 Methods and compositions for prolonging elimination half-times of bioactive compounds |
| 09/18/2002 | EP1240335A2 Proteases |
| 09/18/2002 | EP1240323A2 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors |
| 09/18/2002 | EP1240321A2 MODULATION OF i PAX /i -2 FOR CONTROLLED APOPTOSIS OR SURVIVAL OF CELLS |
| 09/18/2002 | EP1240313A2 Homologues of human heparanase and splice variants thereof |
| 09/18/2002 | EP1240197A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 09/18/2002 | EP1240196A2 Basolateral sorting signal based on scf peptide and inhibitors thereof |
| 09/18/2002 | EP1240195A2 Polynucleotides and polypeptides encoded thereby |
| 09/18/2002 | EP1240194A2 Novel human protein kinases and protein kinase-like enzymes |
| 09/18/2002 | EP1240172A1 New aminopropylphosphinic acids |
| 09/18/2002 | EP1240171A1 Cyclopenteneone derivatives |
| 09/18/2002 | EP1240168A1 Bicyclic inhibitors of glycogen synthase kinase 3 |
| 09/18/2002 | EP1240166A1 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl carboxamide inhibitors of cyclin dependent kinases |
| 09/18/2002 | EP1240165A1 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| 09/18/2002 | EP1240160A1 Substituted pyridazines having cytokine inhibitory activity |
| 09/18/2002 | EP1240153A1 Aminothiazole inhibitors of cyclin dependent kinases |
| 09/18/2002 | EP1240152A1 Ox(adi)azolyl-hydroxamic acids useful as procollagen c-proteinase inhibitors |
| 09/18/2002 | EP1240148A1 Benzo[a]phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase i and ii |
| 09/18/2002 | EP1240147A1 Potassium channel inhibitors |
| 09/18/2002 | EP1240145A2 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof |
| 09/18/2002 | EP1240143A1 New modulators of dopamine neurotransmission |
| 09/18/2002 | EP1240142A1 New modulators of dopamine neurotransmission |
| 09/18/2002 | EP1240141A1 New modulators of dopamine neurotransmission |
| 09/18/2002 | EP1240137A1 Method for making 24(s)-hydroxyvitamin d 2 |
| 09/18/2002 | EP1239897A1 Tissue regenerative composition |
| 09/18/2002 | EP1239883A2 Formulations of adenosine a1 agonists |
| 09/18/2002 | EP1239882A2 Formulations of adenosine a1 agonists |
| 09/18/2002 | EP1239880A2 Formulations of adenosine a1 agonists |
| 09/18/2002 | EP1239878A2 Formulations of adenosine a1 agonists |
| 09/18/2002 | EP1239877A2 MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN $g(a) V?$g(b) 3? RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY |
| 09/18/2002 | EP1239871A1 Use of glp-1 agonists for the inhibition of beta cell degeneration |
| 09/18/2002 | EP1239870A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 09/18/2002 | EP1239868A2 Use of an immunosuppressant for increasing an antifungal activity of a lipopetide |
| 09/18/2002 | EP1239867A2 Methods for treating and preventing damage to mucosal tissue |
| 09/18/2002 | EP1239863A2 Novel glycosidase inhibitors and their pharmacological uses, in particular for treating diabetes |
| 09/18/2002 | EP1239862A2 Pharmaceutical preparation for treating tumor diseases |
| 09/18/2002 | EP1239861A2 Combination of cyamemazine and an atypical neuroleptic |
| 09/18/2002 | EP1239857A1 Dual-release compositions of a cyclooxygenase-2- inhibitor |
| 09/18/2002 | EP1239855A2 Method for the prevention and/or treatment of atherosclerosis |
| 09/18/2002 | EP1239852A2 Bissulfonamide derivatives as enzyme inhibitors |
| 09/18/2002 | EP1239848A2 Compositions and methods for modulating hdl cholesterol and triglyceride levels |
| 09/18/2002 | EP1239843A1 New (aminopropyl)methylphosphinic acids |
| 09/18/2002 | EP1239841A1 Pharmaceutical formulations comprising sodium amoxycilline and potassium clavulanate |
| 09/18/2002 | EP1239839A2 Hydrogel-driven layered drug dosage form comprising sertraline |
| 09/18/2002 | EP1239831A1 Improved pharmaceutical compositions for poorly soluble drugs |
| 09/18/2002 | EP1239826A2 Cosmetic and/or pharmaceutical preparations |
| 09/18/2002 | EP1239824A2 Scar treatment composition comprising a silicone mixture |
| 09/18/2002 | EP1239814A2 Use of the residues from wine production |
| 09/18/2002 | EP1239776A2 Surgical needle with weeping tip and method of use |
| 09/18/2002 | EP1212339A4 2'-o-acetamido modified monomers and oligomers |
| 09/18/2002 | EP1180113A4 Oligonucleotides having a-dna form and b-dna form conformational geometry |
| 09/18/2002 | EP1117633B1 Diaminocyclobutene-3,4-dione derivatives, their preparation and use |
| 09/18/2002 | EP1104762B1 Substituted imidazo[1,2a]azines as selective inhibitors of cox-2 |
| 09/18/2002 | EP1093380B1 Component b as angiogenic agent in combination with human growth factors |
| 09/18/2002 | EP1039884B1 A method for the prevention and treatment of stunned myocardium |
| 09/18/2002 | EP1000034B1 Substituted 6-alkylphenanthridines |
| 09/18/2002 | EP0954565A4 Adipogenic differentiation of human mesenchymal stem cells |
| 09/18/2002 | EP0952837B1 Use of mixtures of active substances, containing phytostenols and/or phytostenol esters and potentiators, for the production of hypocholesteremic agents |